John Farley

ORCID: 0000-0002-5364-8682 · 4 papers in corpus
nonrandomized-trial 2018
Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001)
Gynecologic Oncology ·doi:10.1016/j.ygyno.2018.04.572

OBJECTIVE: To evaluate the efficacy and tolerability of cabozantinib in recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer. METHODS: Patients with recurrent ovarian, fallopian or primary peritoneal tumors with at lea…

2013
Pelvic pain, quality of life (QOL), and exercise in gynecologic cancer patients: A single institution study
·doi:10.1016/j.ygyno.2013.04.135
2013
The characteristics and associations of pelvic pain in gynecologic cancer patients: A single institution study
·doi:10.1016/j.ygyno.2013.07.045
review 2008
Genomic analysis of epithelial ovarian cancer
Cell research ·doi:10.1038/cr.2008.52

Ovarian cancer is a major health problem for women in the United States. Despite evidence of considerable heterogeneity, most cases of ovarian cancer are treated in a similar fashion. The molecular basis for the clinicopathologic characteri…